Sign In
Buy EVLO
$0.0001
+0 (+0%)
At Close: Jun 22, 2026
Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript
02:13pm, Tuesday, 09'th Mar 2021
Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript
Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
07:00am, Tuesday, 09'th Mar 2021
–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and n
Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021
07:00am, Tuesday, 02'nd Mar 2021
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced th
4D Pharma: Impressive Immuno-Oncology Data
06:00pm, Tuesday, 16'th Feb 2021
4D Pharma: Impressive Immuno-Oncology Data
Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More
01:27pm, Saturday, 06'th Feb 2021
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
09:08pm, Thursday, 28'th Jan 2021
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicine
Evelo Biosciences Announces Proposed Public Offering of Common Stock
04:01pm, Thursday, 28'th Jan 2021
CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicine
Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis
07:00am, Wednesday, 20'th Jan 2021
–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured physician-reported outcomes –
Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer
07:00am, Monday, 21'st Dec 2020
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
07:00am, Thursday, 03'rd Dec 2020
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in
Hedge Funds Are Dumping Evelo Biosciences, Inc. (EVLO)
10:47am, Friday, 27'th Nov 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Evelo Biosciences: Clinical Data Coming Soon
10:11am, Tuesday, 10'th Nov 2020
Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system. The approach is novel and unproven and thus investing is a very high risk proposition.
Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights
07:00am, Thursday, 29'th Oct 2020
-- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis ---- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months -
Lowest Insider Activity Since January - The Most Important Insider News (July 2020 Update)
05:51pm, Monday, 03'rd Aug 2020
Insider activity is very informative to follow as insiders know their company better than anyone else.
Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2020 Results - Earnings Call Transcript
06:47am, Sunday, 02'nd Aug 2020
Evelo Biosciences, Inc. (NASDAQ:EVLO) Q2 2020 Earnings Conference Call July 30, 2020 8:30 A.M.
